Lilly Signs a Three-Year Collaboration with Verge Genomics to Discover and Develop Novel Therapies for ALS
Shots:
- Verge to receive ~$25M as up front- equity investment- and near-term payments in addition to ~$694M as milestone and royalties
- The collaboration will utilize Verge’s AI-driven all-in-human platform to identify new targets. Lilly may select up to four identified targets to advance it into clinical development and commercialization
- Verge Genomics retains all rights to its lead program & plans to start clinical trials for its lead program that targets PIKfyve for ALS in 2022
Ref: Businesswire | Image: Venture Beat
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
